Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
|ClinicalTrials.gov Identifier: NCT00278174|
Recruitment Status : Completed
First Posted : January 18, 2006
Last Update Posted : May 4, 2011
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer.
PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Biological: recombinant interferon alpha-1b||Phase 2|
- Determine the objective response rate in patients with metastatic renal clear cell carcinoma treated with interferon alfa-1b.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278174
|United States, Ohio|
|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44195|
|Study Chair:||Ronald M. Bukowski, MD||The Cleveland Clinic|